Abstract | OBJECTIVES: This study sought to identify the role of annexin A1 (AnxA1) as a congestion marker in acute heart failure (AHF) and to identify its putative role in predicting clinical outcomes. BACKGROUND: METHODS: In the Renal Optimization Strategies Evaluation (ROSE) trial, patients hospitalized for AHF with kidney injury were randomized to receive dopamine, nesiritide, or placebo for 72 hours in addition to diuresis. In a subanalysis, plasma AnxA1 levels were measured at baseline and at 72 hours in 275 patients. Participants were divided into 3 tertiles based on their baseline AnxA1 levels. RESULTS: The prevalence of peripheral edema 2+ increased with increasing AnxA1 levels (P < .007). Cystatin C, blood urea nitrogen, and kidney injury molecule-1 plasma levels were higher among participants in tertile 3 vs tertiles 1 or 2 (P< .05). Patients with a congestion score of 4 had a mean baseline AnxA1 level 8.63 units higher than those with a congestion score of 0 (P = .03). Patients in tertiles 2 and 3 were twice as likely to experience creatinine elevation as patients in tertile 1 (P = .03). Patients in tertiles 2 and 3 were at a higher risk of 60-day all-cause mortality or heart failure hospitalization and 180-day all-cause mortality (P < .05). CONCLUSIONS: Among patients hospitalized for AHF with impaired kidney function, elevated AnxA1 levels are associated with worse congestion, higher risk for further creatinine elevation, and higher rates of 60-day morbidity or all-cause mortality and 180-day all-cause mortality. CLINICAL TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01132846.
|
Authors | Fadi W Adel, Aruna Rikhi, Siu-Hin Wan, Seethalakshmi R Iyer, Hrishikesh Chakraborty, Steven McNulty, W H Wilson Tang, G Michael Felker, Michael M Givertz, Horng H Chen |
Journal | Journal of cardiac failure
(J Card Fail)
Vol. 26
Issue 8
Pg. 727-732
(Aug 2020)
ISSN: 1532-8414 [Electronic] United States |
PMID | 32473378
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Copyright | Copyright © 2020 Elsevier Inc. All rights reserved. |
Chemical References |
- Annexin A1
- Biomarkers
- Natriuretic Peptide, Brain
|
Topics |
- Acute Disease
- Annexin A1
- Biomarkers
- Heart Failure
(diagnosis, drug therapy, epidemiology)
- Humans
- Natriuretic Peptide, Brain
- Treatment Outcome
|